News|Articles|November 21, 2026

The OncFive: Top Oncology Articles for the Week of 11/15

Author(s)OncLive Staff
Fact checked by: Caroline Seymour
Listen
0:00 / 0:00

Key Takeaways

  • Giredestrant plus everolimus gained FDA approval for ESR1-mutated ER+/HER2– advanced breast cancer, doubling median PFS versus endocrine therapy plus everolimus and enabling selection via FoundationOne Liquid CDx.
  • European approval of daraxonrasib in post–systemic therapy metastatic pancreatic adenocarcinoma was driven by a large OS improvement and higher ORR than chemotherapy, with manageable rash/diarrhea/stomatitis.
SHOW MORE

The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.

Welcome to OncLive®’s OncFive!

Every week, we bring you a quick roundup of the 5 top stories from the world of oncology—ranging from pivotal regulatory decisions to key pipeline updates to expert insights on breakthroughs that are moving the needle in cancer care. This resource is designed to keep you informed on the latest updates in the space, in just a matter of minutes.

Here’s what you may have missed this week:

FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer

The FDA approved giredestrant (Wilserdly) plus everolimus (Afinitor) for adult patients with estrogen receptor–positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, whose disease has recurred during or after endocrine-based adjuvant therapy or progressed on 1 or more endocrine-based regimens in the metastatic setting. The decision was supported by the randomized, open-label evERA Breast Cancer trial (NCT05306340), in which giredestrant plus everolimus (n = 102) produced a median progression-free survival (PFS) of 10 months (95% CI, 8.1-12.9) vs 5.5 months (95% CI, 3.8-5.6) with physician’s choice of endocrine therapy plus everolimus (n = 105; hazard ratio [HR], 0.38; 95% CI, 0.27-0.54; P < .0001) among patients with ESR1-mutated tumors. In this population, the objective response rates (ORRs) were 27% vs 14%, the median durations of response (DORs) were 14.9 months vs 7.3 months, and the estimated 18-month overall survival (OS) rates were 71.5% vs 50.9% (HR, 0.62; 95% CI, 0.38-1.02), although OS data were not yet mature. In the overall trial population (N = 373), the median PFS was 8.8 months vs 5.5 months, respectively (HR, 0.56; 95% CI, 0.44-0.71; P < .001). The most common any-grade adverse effects (AEs) with giredestrant plus everolimus included stomatitis (47.3%), diarrhea (26.9%), nausea (22.0%), and fatigue (20.9%), and the FDA also authorized FoundationOne Liquid CDx as a companion diagnostic to identify eligible patients.

Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer

The European Commission (EC) approved daraxonrasib (Rasonque) as monotherapy for adult patients with metastatic pancreatic adenocarcinoma previously treated with at least 1 systemic therapy, regardless of whether a RAS mutation has been detected in the tumor. The approval was based on the phase 3 RASolute 302 trial (NCT06625320), in which daraxonrasib (n = 248) produced a median OS of 13.2 months (95% CI, 10.0-not estimable) vs 6.7 months (95% CI, 5.8-8.0) with chemotherapy (n = 252) in the overall population (HR, 0.40; 95% CI, 0.30-0.53; P < .0001), with 12-month OS rates of 53.2% vs 17.3%, respectively, according to data presented at the 2026 ASCO Annual Meeting. In the RAS G12–mutated population, the median OS was 13.2 months vs 6.6 months (HR, 0.40; 95% CI, 0.30-0.54; P < .0001), and the median PFS by blinded independent central review (BICR) was 7.3 months vs 3.5 months (HR, 0.45; 95% CI, 0.34-0.59; P < .0001); the confirmed ORR by BICR in the overall population was 31.6% vs 11.2%. Grade 3 or higher treatment-related adverse effects (TRAEs) occurred in 43.6% of patients treated with daraxonrasib vs 57.5% of those given chemotherapy, TRAEs led to discontinuation in 1.2% vs 11.2%, and the most common TRAEs with daraxonrasib were rash (85%), diarrhea (58%), and stomatitis (53%). In the United States, the FDA approved daraxonrasib on August 26, 2026, for adult patients with metastatic pancreatic adenocarcinoma previously treated with at least 1 systemic therapy or who are ineligible for multiagent systemic therapy.

FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC

The FDA granted accelerated approval to neladalkib (Nelkarmi) for patients with locally advanced or metastatic ALK-positive non–small cell lung cancer (NSCLC) previously treated in the unresectable locally advanced or metastatic setting with alectinib (Alecensa) as their prior ALK-directed tyrosine kinase inhibitor (TKI), or with 2 or more prior ALK-directed TKIs and platinum-based chemotherapy. The approval was supported by the phase 1/2 ALKOVE-1 study (NCT05384626), in which patients previously treated with alectinib (n = 67) achieved an ORR of 49% (95% CI, 37%-62%), with 76% and 52% having a DOR of at least 6 months and 12 months, respectively. Patients who had received 2 or more prior ALK TKIs and platinum-based chemotherapy (n = 155) achieved an ORR of 32% (95% CI, 24%-40%), with 69% and 51% achieving DORs of at least 6 and 12 months, respectively. Treatment-emergent adverse effects (TEAEs) led to dose reductions in 17% of patients (n = 656), most commonly due to increased alanine aminotransferase (ALT; 10%) and aspartate aminotransferase (AST; 8%) levels, and the most common TEAEs were increased ALT (any grade, 47%; grade 3, 20%), increased AST (44%; 16%), constipation (28%), and dysgeusia (23%). Neladalkib previously received breakthrough therapy and orphan drug designations from the FDA, and it is being compared with alectinib in patients with TKI-naive advanced ALK-positive NSCLC in the ongoing phase 3 ALKAZAR trial (NCT06765109).

FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma

The FDA approved a label update for lisocabtagene maraleucel (Breyanzi; liso-cel) in large B-cell lymphoma (LBCL), removing the limitations of use for the CAR T-cell therapy in patients with primary central nervous system lymphoma (PCNSL), making it the second CAR T-cell therapy to receive this update after axicabtagene ciloleucel (Yescarta; axi-cel) in February 2026. In the phase 3 TRANSFORM trial (NCT03575351), which supports the indication for patients with refractory disease or relapse within 12 months of first-line chemoimmunotherapy, liso-cel (n = 92) produced a median event-free survival of 10.1 months (95% CI, 6.1-not reached) vs 2.3 months (95% CI, 2.2-4.3) with standard therapy (n = 92; HR, 0.34; 95% CI, 0.22-0.52; one-sided P < .0001), and the complete response (CR) rates were 66% vs 39%, respectively. In the phase 2 PILOT trial (NCT03483103) of transplant-ineligible patients (n = 61), the ORR was 80% (95% CI, 68%-89%), including a CR rate of 54%. In the LBCL cohort of the phase 1 TRANSCEND NHL 001 trial (NCT02631044), which enrolled patients with relapsed or refractory disease after 2 or more lines of systemic therapy, the ORR was 73% (95% CI, 67%-80%) among efficacy-evaluable patients (n = 192), with a CR rate of 54% and a median DOR of 16.7 months. The prescribing information carries a boxed warning for cytokine release syndrome (CRS), neurologic toxicities, and T-cell malignancies; grade 3 or higher CRS occurred in 1.1%, 1.6%, and 4.1% of patients in TRANSFORM, PILOT, and TRANSCEND NHL 001, respectively.

FDA Issues CRL to Ivonescimab Plus Chemo for Locally Advanced or Metastatic NSCLC

The FDA issued a complete response letter (CRL) to the biologics license application (BLA) seeking approval of ivonescimab (SMT112; AK112), a PD-1/VEGF bispecific antibody, plus platinum-containing chemotherapy for patients with locally advanced or metastatic NSCLC previously treated with an EGFR TKI. The agency determined that substantial evidence of effectiveness was not shown due to the absence of a statistically significant OS improvement vs placebo plus chemotherapy, noting that a PFS benefit without a significant OS benefit does not support a favorable benefit-risk profile. In the phase 3 HARMONi trial (NCT06396065), the median PFS by independent radiology review committee was 6.8 months with ivonescimab plus chemotherapy (n = 172) vs 4.4 months with placebo plus chemotherapy (n = 173; HR, 0.52; 95% CI, 0.41-0.66; P < .0001), whereas the respective median OS values were 16.8 months vs 14.0 months (n = 219 per arm; HR, 0.79; 95% CI, 0.62-1.01; P = .0570). Grade 3 or higher TRAEs occurred in 50.0% vs 42.2% of patients, serious TRAEs occurred in 28.0% vs 15.1%, and grade 3 or higher immune-related AEs occurred in 9.6% vs 6.0%, respectively. Summit Therapeutics said it remains committed to advancing the development of ivonescimab, citing 5 positive phase 3 studies between Summit and Akeso.


Related to this article